Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes
Alessandro Mantovani,
Andrea Dalbeni,
Denise Peserico,
Filippo Cattazzo,
Michele Bevilacqua,
Gian Luca Salvagno,
Giuseppe Lippi,
Giovanni Targher,
Elisa Danese,
Cristiano Fava
Affiliations
Alessandro Mantovani
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
Andrea Dalbeni
Section of General Medicine C and Liver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
Denise Peserico
Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37126 Verona, Italy
Filippo Cattazzo
Section of General Medicine C and Liver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
Michele Bevilacqua
Section of General Medicine C and Liver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
Gian Luca Salvagno
Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37126 Verona, Italy
Giuseppe Lippi
Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37126 Verona, Italy
Giovanni Targher
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
Elisa Danese
Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences, University of Verona, 37126 Verona, Italy
Cristiano Fava
Section of General Medicine C and Liver Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy
A paucity of information currently exists on plasma bile acid (BA) profiles in patients with and without type 2 diabetes mellitus (T2DM). We assayed 14 plasma BA species in 224 patients with T2DM and in 102 nondiabetic individuals with metabolic syndrome. Plasma BA levels were measured with ultra-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) technique. Multivariable linear regression analyses were undertaken to assess associations between measured plasma BA species and T2DM status after adjustment for confounding factors. The presence of T2DM was significantly associated with higher plasma concentrations of both primary BAs (adjusted-standardized β coefficient: 0.279, p = 0.005) and secondary BAs (standardized β coefficient: 0.508, p p p = 0.013) and taurocholic acid (adjusted-standardized β coefficient: −0.309, p = 0.001). This study shows that there are marked differences in plasma BA profiles between patients with and without T2DM. Further research will be needed to better understand how these differences in plasma BA profiles may interplay with the pathophysiology of T2DM.
